Neoplasms by Histologic Type  >>  oxaliplatin  >>  Phase 1
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT02244489: Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Terminated
1b
16
US
Momelotinib (MMB), GS-0387, CYT387, Capecitabine, Oxaliplatin
Sierra Oncology, Inc.
Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
03/17
04/17
NCT00060411: A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

Completed
1
24
US
erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, leucovorin calcium, CF, CFR, LV, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF
National Cancer Institute (NCI)
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
07/07
 
NCT00101270: Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

Completed
1
24
US
irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP
National Cancer Institute (NCI)
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Melanoma, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
09/07
 
NCT00458809: Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer

Completed
1
16
US
oxaliplatin
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Carcinoma of the Appendix, Colorectal Cancer, Primary Peritoneal Cavity Cancer
11/07
11/07
NCT00220649: Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas

Completed
1
25
US
gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin
St. Luke's-Roosevelt Hospital Center, Sanofi
Pancreatic Neoplasms
 
 
NCT01764477: Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

Completed
1
20
US
PRI-724
Prism Pharma Co., Ltd., inVentiv Health Clinical
Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma
10/15
10/15

Download Options